What an Honor It Is...

…To be pinged by the papers for my thoughts and ruminations on the Myogen (NASDAQ: MYOG) and Gilead (NASDAQ: GILD)deal. Christine Tatum and Daily Camera article

• Please let it be known that I am the Assistant Director of the Fitzsimons BioBusiness Incubator (FBBi), a division of the Fitzsimons Redevelopment Authority, and not a venture capitalist as stated in the article. FBBi is supported by the FRA, the State of Colorado, the CU Technology Transfer Office, Metro Denver EDC, Colorado Bioscience Association, the Bard Center for Entrepreneurship, the Aurora Economic Development Council and the Adams County EDC
• Please let it be known that to my understanding Replidyne unlike Myogen has submitted an NDA to the FDA

RE: the Denver Post article

• Product portfolio management is a key component to navigating the drug development waters. Myogen has masterfully managed their risk. Late stage failures, such as with Enoximone, have been known to destroy a company. Many compaines mitigate their risk with mutliple candidate programs but often, and particularly at the earlier stages in company life-cycles, many entities, due to resource constraints, are not afforeded the opportunity to focus upon multiple products and/or multiple indications

Net, I think the deal is great for Colorado life science. It speaks volumes about the quality of the technology, the quality of the universities, the quality of the ability to transfer technology into companies and the quality of the investors and management who are able to architect and execute such companies. The deal rightly so places Colorado in the spotlight and the pipeline behind this deal is equally exciting.